Alnylam's Post-Earnings Legal Storm: Four Firms Circle as Shares Stage a Fragile Comeback
Published on 08/06/2026 at 17:26 | Redaktion boerse-global.de
The sharp selloff that knocked Alnylam Pharmaceuticals to its lowest point in a year has triggered a cascade of legal scrutiny, even as the stock claws back some ground. Four law firms have now opened investigations into the biotech group's handling of its July 30 guidance cut, with the latest — Schall, Brown & Schwartz — announcing its review on Tuesday.
The probe follows a familiar pattern for US-listed companies that disappoint: claims of potential violations of federal securities laws, centered on whether management misled investors about the trajectory of its blockbuster heart-disease drug Amvuttra. Glancy Prongay Wolke & Rotter launched its own examination on Monday, focusing on possible misleading statements tied to the drug's market entry for ATTR-CM, while Bragar Eagel & Squire opened a separate review the same day over the revised 2026 revenue outlook. Bronstein, Gewirtz & Grossman had already flagged buyer claims around the single-day share drop of $81.25 on July 30. None of the four firms has filed a lawsuit yet.
A Record Quarter That Landed With a Thud
The legal interest stems from a quarterly report that delivered a historic first for Alnylam — alongside a forecast that spooked the market. Revenue for the period came in at $1.291 billion, short of the $1.323 billion consensus, while adjusted earnings per share of $1.84 blew past the $1.55 analysts had penciled in. The company also posted its maiden GAAP net profit of $164 million.
The dampener was the cut to full-year guidance for the TTR franchise, trimmed from $4.4–4.7 billion to $4.2–4.5 billion. Management attributed the revision to a "normalization" of second-line therapy growth, arguing that pent-up demand had largely been worked through. The same day brought a mixed bag of external news: Ionis Pharmaceuticals and AstraZeneca revealed that their Phase 3 CARDIO-TTRansform trial for rival drug eplontersen (Wainua) in ATTR-CM had missed its primary efficacy endpoint — a setback for a competitor in the same therapeutic arena — while Alnylam announced an exclusive commercialization pact with BeOne Medicines for AMVUTTRA in China.
Should investors sell immediately? Or is it worth buying Alnylam?
Analysts Split Between Value and Caution
Wall Street's response has been anything but uniform. Raymond James upgraded the stock from Outperform to Strong Buy on Monday, lifting its price target to $420 on what it called an attractive risk-reward profile following the pullback. That bullish call stands against a broader drift lower: the average analyst price target has fallen 11.45 percent in a month to $352.04, down from $397.56 at the end of June. RBC Capital, Stifel, Oppenheimer, Needham and JPMorgan Chase all trimmed their targets in the wake of the earnings report, while H.C. Wainwright reaffirmed its buy rating, citing higher collaboration revenue. Quant platform Wall Street Zen, meanwhile, downgraded the stock from Strong Buy to Hold — an automated signal carrying no fundamental reassessment.
A Bounce, But the Damage Runs Deep
The share price tells a story of partial repair. After touching a 52-week low of €172.15 on the day of the guidance cut, the stock has recovered 11.08 percent over seven trading sessions to €198.00. That leaves it 15.02 percent above the trough — but still down 41.58 percent year-to-date and more than half below its October peak of €425.00. The technical picture remains fragile, with the shares trading well beneath key moving averages and a 30-day annualized volatility of 94.74 percent underscoring how jittery the tape has become.
The central question now is whether Amvuttra can transition from serving backlogged second-line demand to capturing durable first-line share in the ATTR-CM market. Management says new first-line patients are already accounting for the majority of category growth, a signal that the drug is embedding itself as a foundational therapy even as the overall forecast shrinks. The bull case rests on that operational momentum plus a valuation that has become historically cheap; the consensus target of €334.45 implies roughly 70 percent upside from recent levels. The bear case points to a market that may simply grow more slowly than modeled, with further downward revisions possible if first-line uptake fails to offset the second-line slowdown.
Alnylam at a turning point? This analysis reveals what investors need to know now.
Pipeline catalysts could shift the narrative. Alnylam has scheduled first Phase 1 data for ALN-HTT02 in Huntington's disease for October 23 at the European Huntington's Disease Network congress in Krakow, while Phase 1 and Phase 2 readouts for ALN-6400 and Phase 1 results for ALN-2232 are due in the second half. Earlier this year, the company also struck an AI-RNAi partnership with Inceptive in June and a licensing deal with Tenaya Therapeutics in March — collaborations that could bolster the longer-term story if they deliver tangible progress.
For now, the key technical markers are clear: holding above €172.15 suggests consolidation with a gradual upward bias, while reclaiming the 50-day moving average at €247.17 would signal a more structural turn. A slip back below the low, or an escalation of legal pressure, would put the year's already substantial losses at risk of widening further.
Ad
Alnylam Stock: New Analysis - 6 August
Fresh Alnylam information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
